Video highlights from the San Antonio Breast Cancer Symposium (SABCS) 2024, taking place in San Antonio, TX from December 10 to 13, 2024.
These clips will provide invaluable insights and updates on Breast Cancer research from SABCS 2024.
December 10 – Dr. Christos Sotiriou
Dr. Christos Sotiriou highlights the identification of five different subtypes of breast cancer and the application of advanced technologies to analyze tissues and tumors.
December 11 – Dr. Gabe S. Sonke
Dr. Gabe S. Sonke discusses various studies on breast cancer treatments, including the effectiveness of new drugs, neoadjuvant chemotherapy strategies, and the benefits of remote symptom monitoring for patients with advanced breast cancer.
December 12 – Dr. Fatima Cardoso
Dr. Fatima Cardoso discusses two potentially practice-changing studies, focusing on advanced breast cancer treatments and their implications for clinical practice.
December 12 – Dr. David Mankoff
Dr. David Mankoff discusses the increasing role of imaging in breast cancer research, highlighting the use of molecular imaging and artificial intelligence to improve diagnosis, treatment, and discovery of new therapeutic pathways.
December 12 – Dr. Carlos Barrios
Dr. Carlos Barrios discusses the PATINA trial that was presented recently.
December 12 – Dr. David Mankoff
Dr. David Mankoff discusses the multidisciplinary approach to breast cancer research, highlighting the collaboration between scientific and patient communities.
December 12 – Dr. Fatima Cardoso
Dr. Fatima Cardoso emphasizes the need for systemic changes in breast cancer care, particularly in communication and support for metastatic breast cancer patients.
December 13 – Dr. Virginia Kaklamani
Dr. Virginia Kaklamani highlights the EMBER-3 clinical trial, which found that imlunestrant outperformed single-agent endocrine therapy in patients with ESR1 mutations and showed improvement when combined with abemaciclib, suggesting potential FDA approval.
December 13 – Dr. Virginia Kaklamani
Dr. Virginia Kaklamani discusses the PATINA trial, a phase III clinical trial.
December 13 – Dr. Virginia Kaklamani
The TAILORx trial data presented by Dr. Virginia Kaklamani at SABCS highlights that anthracyclines are beneficial for patients with estrogen-positive early-stage breast cancer and a high genomic risk score, suggesting it may become a standard of care.